Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

NEW YORK, December 30, 2025, 15:32 ET — Regular session GRAIL Inc shares were down 3.3% at $84.95 in afternoon trading on Tuesday, after earlier touching $84.77. The early-cancer detection company is trying to turn Galleri — a multi-cancer early detection (MCED) blood test that screens for signals across many cancers from a single draw — into a mainstream part of care. In its most recent quarterly update, Grail said U.S. Galleri revenue rose 28% year-on-year to $32.6 million and test volumes increased 39%, while it anticipated completing a U.S. premarket approval filing in the first quarter of 2026. GRAIL
30 December 2025
··
Upwork stock drops 3% today as UPWK slips below $20 with earnings ahead

Upwork stock drops 3% today as UPWK slips below $20 with earnings ahead

NEW YORK, December 30, 2025, 15:28 ET — Regular session Upwork Inc shares were last down 3.4% at $19.60 on Tuesday, after dipping as low as $19.60 in the session. The stock, valued at about $2.46 billion, was sliding even as the S&P 500 and Nasdaq-100 proxies were only modestly lower. The move matters because Upwork has been trading as a profitability-and-execution story, leaving the stock prone to sharp swings when investors rotate away from smaller growth names. A fall below the $20 level also puts a spotlight on near-term technical support, with traders watching whether the stock can reclaim
30 December 2025
··
Hut 8 stock today: Why HUT is down even as bitcoin edges higher

Hut 8 stock today: Why HUT is down even as bitcoin edges higher

NEW YORK, December 30, 2025, 15:21 ET — Regular session Hut 8 Corp (HUT) shares fell 3.1% to $47.31 in afternoon trading on Tuesday, after moving between $47.18 and $49.26 earlier in the session. About 2.26 million shares had traded. The pullback matters because Hut 8 sits at the intersection of two fast-moving themes: bitcoin-linked equities and the market’s scramble for data centers to run artificial intelligence (AI) workloads. That mix has made the stock prone to sharp, sentiment-driven swings. The broader backdrop has been choppy. U.S. stocks were subdued on Tuesday and trading volumes remained thin in the holiday-truncated
30 December 2025
····
TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

NEW YORK, December 30, 2025, 15:14 ET — Regular session Shares of TIC Solutions, Inc. (TIC) fell about 3.5% to $10.02 in afternoon trading on Tuesday, underperforming a largely steady U.S. equity market. The stock last closed at $10.38. The decline came in holiday-thin trade as investors recalibrated rate expectations after the Federal Reserve’s December-meeting minutes hit the tape. “At the end of the day, solid corporate profits can make up for a lot of sins,” said Ryan Detrick, chief market strategist at Carson Group. Reuters The slide matters for TIC because investors have been focused on execution rather than
30 December 2025
··
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

NEW YORK, December 30, 2025, 15:16 ET — Regular session Travere Therapeutics Inc shares were down about 3.8% at $37.39 on Tuesday afternoon, extending losses after recent insider-trading disclosures. The stock traded between $37.27 and $39.20, with about 893,000 shares changing hands. (TVTX quote) The selling matters because it lands just weeks before a major regulatory milestone for the rare-disease drugmaker. Traders often react to clusters of insider sales — even when they are planned — as they reassess near-term positioning. Travere, based in San Diego, markets Filspari for a kidney disease called IgA nephropathy, and is seeking an expansion
30 December 2025
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

NEW YORK, December 30, 2025, 2:30 PM ET — Regular session Shares of Catalyst Pharmaceuticals, Inc. fell 3.0% to $23.33 in afternoon trading on Tuesday. The stock has traded between $23.30 and $24.10 so far in the session. The drop matters because trading can get choppy in the final days of the year, when fewer investors are active and price moves can be exaggerated. Mid-cap healthcare names often swing more than the major indexes in that setting. Catalyst fell 1.2% on Monday to close at $24.06, according to MarketWatch data, and it remains well below its June 9 52-week high
30 December 2025
··
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

NEW YORK, December 30, 2025, 14:30 ET — Regular session Shares of Kymera Therapeutics fell about 3% to $77.94 in afternoon trading on Tuesday, lagging a broader biotech dip. The SPDR S&P Biotech ETF was down about 1.4%, while the iShares Nasdaq Biotechnology ETF slipped about 1.1%. The pullback matters because Kymera has been one of the sector’s higher-volatility names this month, after a surge tied to new clinical data and a subsequent stock sale that increased its share count. With most of its next major readouts still far off, investors have been quick to reprice the stock around financing
30 December 2025
··
Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

NEW YORK, December 30, 2025, 3:07 PM ET — Regular session Shares of Almonty Industries Inc fell about 3.9% to $8.90 in afternoon trading on Tuesday after giving up an early rise, with the stock swinging between $8.90 and $9.39. The pullback comes as investors focus on tungsten, a hard metal used in munitions, industrial tooling and electronics, at a moment when governments are pushing to secure strategic supply chains. A CBS News report published on Monday said Chief Executive Lewis Black met U.S. officials, including at the White House, before touring Almonty’s Sangdong mine in South Korea and signing
30 December 2025
···
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

NEW YORK, December 30, 2025, 14:54 ET — Regular session Shares of Praxis Precision Medicines Inc (NASDAQ: PRAX) slipped about 3% on Tuesday, giving back part of a sharp rally sparked by an FDA regulatory boost for its lead essential tremor program. The stock was down 3% at $295.50 as of 2:39 p.m. ET, after opening at $304.00 and trading between $286.58 and $304.70. The company said on Monday the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for ulixacaltamide to treat essential tremor, and said the decision was based on positive topline results from the Essential3 program, two
30 December 2025
··
Why Caris Life Sciences (CAI) stock is down today as biotech slips

Why Caris Life Sciences (CAI) stock is down today as biotech slips

NEW YORK, December 30, 2025, 14:58 ET — Regular session Caris Life Sciences shares were down about 1.8% at $27.44 as of 2:41 p.m. ET, after trading between $27.00 and $27.97 during Tuesday’s session. The drop came as biotech stocks underperformed, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.2%. The S&P 500 was little changed and the Nasdaq was flat, Reuters data showed. Reuters That matters for Caris because the newly public cancer diagnostics company tends to move with shifts in risk appetite for healthcare growth names, even when there
30 December 2025
Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

NEW YORK, December 30, 2025, 14:40 ET — Regular session Shares of Cogent Biosciences, Inc. fell 2.7% to $36.88 on Tuesday after the biotech said it submitted a New Drug Application to the U.S. Food and Drug Administration for its drug candidate bezuclastinib in nonadvanced systemic mastocytosis. Yahoo Finance An NDA is the formal request asking the FDA to review a drug for marketing approval, a key inflection point for development-stage biotechs with no products on the market. U.S. Food and Drug Administration Systemic mastocytosis is a rare disorder marked by abnormal accumulation and activation of mast cells — immune
30 December 2025
··
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

NEW YORK, December 30, 2025, 14:45 ET — Regular session Arcutis Biotherapeutics shares fell 2.9% to $27.74 in afternoon trading on Tuesday, after moving between $27.72 and $28.65. Volume was about 0.6 million shares. The drop outpaced broader biotech gauges, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.1%. That matters for Arcutis because it trades as a growth story tied to one product franchise, leaving the stock prone to outsized moves when sentiment sours across biotech and high-multiple names. Arcutis is a commercial-stage medical dermatology company whose main product, Zoryve
30 December 2025
·
Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

NEW YORK, December 30, 2025, 2:26 PM ET — Regular session Vera Therapeutics, Inc. shares slid 3.4% to $50.45 in afternoon trading on Tuesday, giving back some recent gains as biotech stocks softened late in the year. The move matters now because Vera has become a bellwether “event-driven” biotech name, where day-to-day trading can swing sharply as investors calibrate risk around FDA timelines and competitive positioning in kidney disease. Thin year-end liquidity can amplify those swings, and traders have been quick to trim exposure to smaller, higher-beta healthcare names when the sector loses momentum. Minutes from the Federal Reserve’s December
30 December 2025
··
Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

NEW YORK, December 30, 2025, 2:20 PM ET — Regular session Shares of Ares Management Corp fell 3.1% to $163.85 in afternoon trading on Tuesday, down $5.20 from Monday’s close. The stock traded between $168.99 and $163.49, with about 966,000 shares changing hands. The move matters because Ares is closely tied to credit-market conditions. Investors are weighing where interest rates settle in early 2026 and what that means for fundraising, deal activity and returns in private credit. A Reuters Breakingviews column said private credit is losing some of its pricing edge as bank-led bond and loan markets regain momentum, pushing
30 December 2025
··
Soleno Therapeutics stock slides today: SLNO drops on investor-alert headline as biotech sector slips

Soleno Therapeutics stock slides today: SLNO drops on investor-alert headline as biotech sector slips

NEW YORK, December 30, 2025, 2:16 PM ET — Regular session Shares of Soleno Therapeutics, Inc. fell 3.1% to $46.09 in afternoon trading on Tuesday, after a law firm said it was investigating potential claims on behalf of investors. The drop outpaced declines in biotech benchmarks, with the SPDR S&P Biotech ETF down about 1.4% and the iShares Nasdaq Biotechnology ETF off about 1.1%. The move matters because Soleno is still in the early innings of commercializing its first marketed drug, and the stock has traded with sharp swings as investors debate demand, safety perception and pricing power. Legal headlines
30 December 2025
Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names

Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names

NEW YORK, December 30, 2025, 14:21 ET — Regular session Karman Holdings Inc. shares were down 3.6% at $74.81 in afternoon trading on Tuesday, after touching $74.21 at the session low. The stock traded as high as $78.55, with about 465,000 shares changing hands. The dip comes in the final week of the year, when thinner liquidity can exaggerate moves in individual stocks. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide, in a broader market note on holiday-thin trading. Fund flows have also become a near-term
30 December 2025
··
Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

NEW YORK, December 30, 2025, 02:05 PM ET — Regular session Zenas BioPharma Inc shares fell $2.02, or 5.2%, to $37.03 in afternoon trading on Tuesday, after ending the prior session at $39.05. The stock ranged from $36.94 to $40.50, with about 123,000 shares traded. The drop came as biotech stocks eased in thin year-end trading, with the Nasdaq Biotechnology Index down about 1%. That matters now because smaller, cash-burning drug developers often move with risk appetite as much as on headlines. indexes.nasdaqomx.com Wall Street’s main indexes were largely muted as investors waited for minutes from the Federal Reserve’s December
30 December 2025
··
BETA Technologies stock slides in year-end trade: what’s driving the move and what investors watch next

BETA Technologies stock slides in year-end trade: what’s driving the move and what investors watch next

NEW YORK, December 30, 2025, 14:01 ET — Regular session Shares of BETA Technologies, Inc. (BETA) fell 3.4% to $28.46 in afternoon trading on Tuesday after opening at $29.82, leaving the stock near the day’s low of $28.37. The session high was $29.79, with about 304,000 shares traded. The drop came as U.S. stocks held near flat in choppy, holiday-thinned trading, with investors focused on minutes from the Federal Reserve’s Dec. 9-10 meeting due later in the day. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide.
30 December 2025
·
Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

NEW YORK, December 30, 2025, 13:47 ET — Regular session Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares were down 3.6% at $67.09 at 1:47 p.m. ET on Tuesday, after trading between $65.94 and $69.95. The stock’s drop came as biotech weakened but the wider market held steady, a setup that can amplify moves in higher-volatility drug developers. The SPDR S&P Biotech ETF (XBI) fell 1.3% and the iShares Nasdaq Biotechnology ETF (IBB) dropped 1.1%, while the S&P 500 tracker SPY was flat and the Nasdaq-100 proxy QQQ edged higher. The timing matters because Arrowhead is heading into an early-January news window where
30 December 2025
··
Freshpet stock slides as Fed minutes loom in thin year-end trade (FRPT)

Freshpet stock slides as Fed minutes loom in thin year-end trade (FRPT)

NEW YORK, December 30, 2025, 1:59 PM ET — Regular session Freshpet, Inc. shares were down 3.5% at $60.84 by 1:59 p.m. ET on Tuesday, extending a choppy stretch for the pet food maker’s stock. The slide stood out against an otherwise muted session, a reminder that thinner year-end liquidity can exaggerate moves in single names. The stock’s drop also comes hours before the Federal Reserve releases minutes from its December policy meeting at 2 p.m. ET — a closely watched readout that can shift rate expectations and, by extension, valuations for stocks priced on future growth. https://www.reuters.com/business/final-fed-minutes-2025-shed-light-policy-divisions-2025-12-30/ U.S. stocks
30 December 2025
··
1 … 287 288 289 290 291 … 535

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Go toTop